Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Delisting risk
confidence 92%
filed 2026-08-06
EX-99.1
The press release announces that Zhengye has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after previously falling below that threshold for 30 consecutive business days (notification received May 29, 2026). While the announcement is positive (regaining compliance), it discloses a material delisting risk event—the Company was in non-compliance with a continued listing standard and faced potential delisting. The disclosure of the prior non-compliance and the path to remediation is material to investors assessing listing status and regulatory standing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-06
The filing announces that AXIA Energia's ADRs will cease trading on the NYSE after August 6, 2026, and migrate to the OTC market. The Company will simultaneously file Form 15F to deregister its securities and suspend reporting obligations under the Securities Exchange Act of 1934, with deregistration expected to become effective 90 days after filing. This constitutes a delisting from a national securities exchange and a material change in the registrant's listing status and regulatory obligations.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-06
Item 3.01
Accuray received approval to transfer its listing from The Nasdaq Global Select Market to The Nasdaq Capital Market, a lower-tier listing, and was granted a 180-day cure period to meet the $1.00 bid price requirement. This transfer signals failure to satisfy continued listing standards on the higher tier and represents material delisting risk under Item 3.01, as it directly affects the registrant's market standing and investor access.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-06
Jupiter Neurosciences executed a 1-for-75 reverse stock split, explicitly stated to be "intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market." This disclosure directly addresses delisting risk and the company's remedial action to avoid it, making this a material delisting-risk event.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-06
The filing discloses that Beyond Air regained compliance with Nasdaq's minimum bid price rule following a reverse stock split, but is now subject to a one-year Discretionary Panel Monitor period with heightened delisting risk. The filing explicitly states that failure to maintain any continued listing requirement during the Monitor Period will result in immediate delisting determination without opportunity to submit a compliance plan—a material change in the company's listing status and risk profile that would affect investor assessment.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-05
EX-99.1
NaaS announced that it has regained compliance with Nasdaq's minimum market value of listed securities (MVLS) requirement after previously failing to maintain the $35 million threshold. The company was notified of non-compliance on February 17, 2026, and has now confirmed restoration of compliance as of August 4, 2026. This disclosure directly addresses delisting risk under Nasdaq Listing Rule 5550(b)(2), making it material to investors assessing the company's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-05
Item 3.01
The filing discloses that Destination XL Group failed to maintain Nasdaq's minimum bid price requirement of $1.00 per share and has been granted a transfer to the Nasdaq Capital Market with an additional 180-day compliance period ending February 1, 2027. The disclosure explicitly states that if the Company cannot regain compliance by that date, "the Staff will provide written notification that the Company's common stock will be delisted." This is a classic delisting-risk disclosure under Item 3.01, with material consequences for shareholders if the Company fails to cure the deficiency.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-05
Item 3.01
The filing discloses that Genprex has regained compliance with Nasdaq's $1.00 Minimum Bid Price requirement after previously being at risk of delisting. While the immediate delisting threat has been lifted, the Panel maintains jurisdiction through December 7, 2026, and the Company faces continued delisting risk if it fails to maintain the bid price or violates other listing rules. This is a material disclosure of delisting risk and conditional compliance status under Item 3.01.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-05
EX-99.1
The exhibit announces that Cheche Group has regained compliance with Nasdaq's minimum bid price requirement (Listing Rule 5550(a)(2)) after previously falling below the US$1.00 threshold. While the announcement is positive (compliance regained), it discloses a material delisting risk event—the company's prior non-compliance with a continued listing standard and the cure mechanism employed. The disclosure directly addresses Nasdaq listing qualification status, which is material to investors assessing the registrant's continued public trading eligibility.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-08-05
EX-99.1
Magnitude International announced receipt of a Nasdaq Staff Delisting Determination dated August 3, 2026, stating that Nasdaq has determined to delist the Company's securities pursuant to Nasdaq Listing Rule IM-5101-4. The delisting follows a temporary SEC trading suspension (December 5–18, 2025) and subsequent Nasdaq trading halt (December 19, 2025). Although the Company intends to request a hearing that will stay the delisting pending a Hearings Panel decision, the formal delisting determination is a material event that directly threatens the Company's continued listing and market access.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-05
EX-99.1
Li Bang International announced a 1-for-200 reverse share split explicitly "to help ensure the Company's continued compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2)." This disclosure directly addresses delisting risk — the company is taking corrective action to avoid falling below Nasdaq's minimum bid price threshold, a core continued-listing standard. The announcement is material because it signals the company was at risk of non-compliance with exchange listing rules.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-05
Item 3.01
Upland Software received a deficiency notice from Nasdaq on July 31, 2026, for failing to meet the $15 million minimum market value of publicly held shares requirement under Nasdaq Listing Rule 5450(b)(2&3)(C). The company has 180 days until January 27, 2027, to regain compliance, with explicit warning that failure to do so will result in a delisting notice. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-05
Item 3.01
Vistagen received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). The company has not yet cured the deficiency and faces potential delisting if it fails to comply by February 1, 2027. This is a classic delisting-risk disclosure under Item 3.01, materially affecting the company's continued listing status and investor confidence.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 87%
filed 2026-08-05
Item 5.03
iPower Inc. announced a 1-for-9 reverse stock split effective August 7, 2026, explicitly undertaken to increase the per-share trading price and maintain compliance with The Nasdaq Capital Market's minimum bid price requirement for continued listing. The reverse split was approved by stockholders and the board, signaling the company was at risk of delisting and took corrective action to avoid falling below Nasdaq's listing standard.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-04
EX-99.1
G. Willi-Food announces its voluntary delisting from NASDAQ and intention to deregister from SEC reporting obligations, concentrating trading solely on the Tel Aviv Stock Exchange. The company states it will file Form 25 on or about August 17, 2026, with the last trading day expected no earlier than August 26, 2026, and Form 15F on or about August 28, 2026. This is a material change in listing status that directly affects where and how shareholders can trade the company's shares and fundamentally alters the regulatory framework governing the company.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-04
Item 3.01
VSee Health received a Staff Delisting Determination from Nasdaq on July 30, 2026, indicating that the Company's securities will be delisted from the Nasdaq Capital Market effective August 6, 2026, due to failure to maintain the minimum $1.00 bid price requirement and triggering the $0.10 or less closing bid price rule for ten consecutive trading days. This is a definitive delisting notice, not merely a risk or warning, making it a material event that fundamentally affects the registrant's public market status and investor access to the securities.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-04
EX-99.1
CBL International announced on August 3, 2026, that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after previously receiving a delisting notice on August 12, 2025. The company effected a 1-for-13 reverse stock split on July 20, 2026, to cure the deficiency. While the announcement is positive (compliance regained), the underlying event is the resolution of a delisting risk that threatened the company's continued listing on Nasdaq, making this material to investors assessing the registrant's exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-04
The filing discloses that Mangoceuticals received a deficiency notification from Nasdaq on February 4, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. On August 4, 2026, the company received a Second Notice granting an additional 180-calendar-day compliance period until February 1, 2027, to regain compliance with the Bid Price Requirement. This is a material delisting risk disclosure under Item 8.01, as the company faces potential delisting if it fails to meet the minimum bid price requirement by the deadline.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 90%
filed 2026-08-04
Item 3.01
Bed Bath & Beyond announced a voluntary transfer of its principal listing from NYSE to Nasdaq, effective August 17, 2026, with concurrent corporate name change to Neighborhood Intelligence, Inc. and ticker symbol change to NXH (common stock) and BBBY WS (warrants).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-04
Item 8.01
The disclosure centers on Nasdaq's determination that Sadot Group now complies with minimum stockholders' equity requirements after previously failing to meet them (May 5, 2026 notice). However, the Compliance Letter explicitly warns that if the Company fails to evidence compliance upon filing its September 30, 2026 periodic report, "the Company may be subject to delisting" with no assurance of future compliance. This is a classic delisting-risk disclosure under Item 8.01, as it describes the registrant's conditional compliance status and material threat of delisting contingent on future financial performance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-04
Item 8.01
Expion360 regained compliance with Nasdaq listing requirements after previously receiving a staff determination on January 29, 2026, that its stock had fallen below the $1.00 minimum bid price requirement. The company maintained a closing price above $1.00 for ten consecutive trading days and received confirmation of compliance from Nasdaq's Office of General Counsel on August 4, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-03
Item 8.01
The Board authorized senior management to terminate the Company's Securities Exchange Act registration and file a Form 15 on or after August 10, 2026. Upon filing, SEC reporting obligations (10-K, 10-Q, 8-K) will be suspended and deregistration will become effective 90 days later. While the Company anticipates shares will continue trading on OTC Markets, this disclosure represents a material change in listing status and regulatory obligations that directly affects investor access to SEC-filed financial information.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-03
Item 8.01
Flutter Entertainment announced the completion of cancellation of its secondary listing on the London Stock Exchange effective August 3, 2026, with shares now trading only on the NYSE. This is a delisting event—the removal of the company's shares from a major exchange listing. While the company maintains its primary NYSE listing and this is an orderly, planned delisting rather than a forced one, it materially affects the trading venues available to shareholders and represents a significant change in the company's listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-03
EX-99.1
The press release announces that Hub Cyber Security has regained full compliance with Nasdaq's Market Value of Listed Securities (MVLS) requirement of $35 million after receiving a deficiency notice on January 21, 2026. The Nasdaq Staff confirmed on July 31, 2026 that the Company had maintained the required threshold for 20 consecutive business days and the matter is now closed. This disclosure directly addresses a delisting risk that previously threatened the Company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-03
The filing discloses that Hashdex Commodities Trust (Hashdex Bitcoin ETF, ticker DEFI) has authorized a plan to liquidate the Fund, terminate its continuous offering, and deregister its shares under Section 12(b) of the Exchange Act. Trading will be suspended after August 17, 2026, and the Fund will be delisted from NYSE Arca following a Form 25 filing. This is a terminal delisting event driven by the sponsor's decision to close the fund due to low assets under management ($14.7 million) and operational considerations.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-03
EX-99.1
The press release discloses that Nuvini received a Nasdaq staff determination letter on July 28, 2026 stating that the Company failed to regain compliance with the minimum Market Value of Listed Securities requirement ($35 million) by the July 27 deadline. The letter indicates trading would be suspended and a Form 25-NSE would be filed absent a hearing request. Although the Company has requested a hearing that stays suspension, the disclosure explicitly addresses delisting risk and the Company's plan to regain compliance under an alternative listing standard, making this a material delisting-risk disclosure under Item 3.01 equivalent.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-03
Item 3.01
Alzamend Neuro disclosed non-compliance with Nasdaq Listing Rule 5605(b)(1) requiring a majority independent board, triggered by the death of an independent director. Nasdaq has provided a cure period through July 20, 2027 (or earlier if the annual meeting occurs before January 18, 2027), with material uncertainty about whether compliance will be achieved within the cure period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-08-03
EX-99.1
The exhibit announces that J-Star has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement, following a hearing on July 21, 2026. The company's ordinary shares maintained a closing bid price of at least $1.00 per share for 10 consecutive trading sessions, resolving the delisting risk. This is a material disclosure because it directly addresses a continued listing standard and the resolution of a prior compliance deficiency that threatened the company's Nasdaq listing.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-03
The 6-K discloses that GrowHub received a Staff Determination Letter from Nasdaq on June 5, 2026, notifying the Company of delisting from The Nasdaq Capital Market due to failure to meet minimum bid price and stockholders' equity requirements. Although the Company successfully appealed and received an exception to continue listing (Decision Letter dated July 29, 2026), the core disclosure is the delisting determination and the conditional exception granted, which directly implicates Item 3.01 (Delisting or Transfer of Listing). The exception is conditioned on demonstrating compliance with initial listing standards by December 2, 2026, and the Merger's completion remains uncertain, creating material delisting risk.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-03
Item 5.03
CloudAstructure implemented a 1-for-30 reverse stock split effective July 31, 2026, explicitly to regain and maintain compliance with Nasdaq Capital Market's $1.00 minimum bid price requirement under Listing Rule 5550(a)(2). The company's stock price had fallen below the minimum threshold, triggering this corrective action to avoid delisting.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 98%
filed 2026-08-03
EX-99.1
SU Group received a written delisting determination from Nasdaq on August 3, 2026, for failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company intends to request a hearing before a Nasdaq Hearings Panel to appeal the determination. This is a classic delisting-risk disclosure under Item 3.01 equivalent, as it notifies investors of the registrant's failure to satisfy a continued listing rule and the risk of delisting unless compliance is regained or the Panel grants relief.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-03
Item 8.01
AEON Biopharma announced it has regained compliance with NYSE American's continued listing standards after resolving stockholders' equity deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. The company received written notice from NYSE Regulation confirming resolution of the deficiencies and expects removal of the '.BC' (below compliance) indicator from its trading symbol.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
EX-99.1
YXT.com announced that it has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share after being notified of non-compliance on January 28, 2026. The company changed its ADS ratio from 1:3 to 1:30 to restore compliance. This disclosure directly addresses a delisting risk — the failure to maintain a continued listing standard — and confirms resolution of that risk as of July 30, 2026.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Item 3.01
Traws Pharma received a notification from Nasdaq on July 29, 2026, that it failed to meet the minimum bid price requirement (closing bid below $1.00 per share for 30+ consecutive business days) under Nasdaq Listing Rule 5550(a)(2). The company has 180 days until January 25, 2027, to regain compliance or face delisting. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued public listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Item 3.01
Humacyte received formal notification from Nasdaq on July 31, 2026, that its common stock bid price closed below the $1.00 minimum requirement for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5450(a)(1). The company has been granted a 180-calendar-day compliance period (until January 27, 2027) to regain compliance by achieving a closing bid price of $1.00 or more for 10 consecutive business days. This is a classic delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the registrant's continued exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Item 3.01
PDS Biotechnology received a deficiency letter from Nasdaq on July 30, 2026, notifying the company that its closing bid price has fallen below the $1.00 minimum required under Nasdaq Listing Rule 5550(a)(2). The company has been granted a 180-day compliance period (until January 26, 2027) to regain compliance, with the explicit warning that failure to do so will result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-31
Item 3.01
As a result of the merger completion, the Company's Common Stock ceased trading on Nasdaq Capital Market on July 30, 2026. The Company requested suspension and removal from listing and intends to file Form 15 to deregister the Common Stock and suspend reporting obligations under the Exchange Act.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 75%
filed 2026-07-31
Item 8.01
The filing announces the Company's failure to consummate a business combination before the Completion Window expires on August 12, 2026, triggering mandatory liquidation, redemption of public shares at ~$11.47/share, and delisting from Nasdaq. The Company explicitly states "The last day that the Company's securities will trade on The Nasdaq Stock Market LLC ("Nasdaq") will be August 12, 2026" and intends to file Form 15 to suspend reporting obligations. While this is a terminal event for a SPAC, the most salient disclosure is the imminent delisting and loss of public trading status, which is material to all shareholders.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-31
Item 3.01
Columbus Acquisition Corp received notice from Nasdaq on July 28, 2026 that it failed to meet Listing Rule 5450(a)(2) (the "Minimum Holders Rule") as of May 22, 2026. Although Nasdaq granted an extension through November 18, 2026 to regain compliance, the company remains at risk of delisting if it cannot satisfy the minimum holders requirement by that deadline. This is a material disclosure of delisting risk under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-07-31
Item 8.01
The Company received formal notice from Nasdaq on July 29, 2026 that it has "regained compliance" with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2), and that "this matter is now closed." This disclosure directly addresses a delisting risk — the prior non-compliance with the bid price rule that threatened continued listing. The resolution of this compliance deficiency is material to investors assessing the registrant's exchange listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Item 3.01
Nasdaq notified UPEXI on July 30, 2026, that the Company failed to maintain the minimum bid price of $1.00 per share for 30 consecutive business days, triggering a delisting notice under Nasdaq Listing Rule 5550(a)(2). Although the Company has been granted a 180-calendar-day compliance period until January 26, 2027, the notification letter itself constitutes a material delisting risk disclosure under Item 3.01, as it signals potential loss of listing if compliance is not regained.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
EX-99.1
The exhibit announces that Diginex has regained compliance with Nasdaq's Minimum Bid Price Requirement (Rule 5550(a)(2)) after receiving a non-compliance notice on March 23, 2026. The company had been below the $1.00 minimum bid price threshold and faced a 180-day cure period ending September 21, 2026. This disclosure directly addresses delisting risk — the core material event is the company's prior non-compliance and the regulatory jeopardy it created, now resolved. The announcement of regained compliance is material because it resolves an existential threat to the company's continued listing on Nasdaq.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-31
The filing discloses that Nasdaq imposed a trading halt under Code T12 on June 12, 2026, and that the halt is now being lifted on July 31, 2026. Code T12 halts are typically issued for non-compliance with continued listing standards or disclosure requirements. While the company states it is "not aware of any material, undisclosed corporate developments," the fact that a trading halt was imposed and is only now being lifted signals a delisting risk event that would materially affect investor assessment of the registrant's listing status.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
Galmed received notice from Nasdaq on July 30, 2026, that it has failed to maintain the minimum $1 bid price per share requirement and has been granted an additional 180-day compliance period (until January 25, 2027) to cure the deficiency. This is a classic delisting-risk disclosure under Item 3.01 — the company faces potential delisting if it cannot regain compliance within the extended cure period.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
EX-99.1
Core AI received a Nasdaq notification on July 31, 2026 that it failed to maintain the minimum $1.00 bid price requirement for 30 consecutive trading days (June 17–July 30, 2026). The company has 180 days to regain compliance or faces delisting; if it fails to cure and does not qualify for a second compliance period, Nasdaq will issue a delisting determination. This is a material disclosure of delisting risk under the taxonomy.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
Mira Pharmaceuticals received a notice from Nasdaq on July 27, 2026, that it failed to maintain the minimum bid price of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company has been given 180 calendar days until January 25, 2027, to regain compliance, with the explicit warning that failure to do so could result in delisting. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 85%
filed 2026-07-31
The filing discloses a 1-for-16 reverse stock split effected on July 30, 2026, explicitly stated as "a proactive measure intended to increase the per-share trading price, support the continued listing of its Common Stock on the NYSE American and reduce the risk that its Common Stock could become subject to delisting for failure to satisfy applicable continued listing standards." This is a material governance action directly addressing delisting risk under continued listing standards.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-31
bioAffinity Technologies received written notice from Nasdaq on July 30, 2026 that it failed to maintain the minimum bid price requirement of $1.00 per share for 30 consecutive business days and is not in compliance with Nasdaq Listing Rule 5550(a)(2). The company is ineligible for the standard 180-day compliance period due to a prior reverse stock split, creating immediate delisting risk. The company intends to appeal but faces substantial uncertainty about maintaining its listing on the Nasdaq Capital Market.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 95%
filed 2026-07-31
EX-99.1
Uni-Fuels received a Nasdaq notification letter dated July 27, 2026, stating the company is not in compliance with the minimum closing bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until January 25, 2027 to regain compliance, with a potential additional 180-day cure period if certain conditions are met. Failure to comply could result in delisting. This is a material disclosure of delisting risk that would significantly affect a reasonable investor's assessment of the registrant's continued listing status.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-07-31
Item 3.01
DocGo received notice from Nasdaq on July 28, 2026 that it has failed to satisfy the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) and has been granted an additional 180 calendar days (until January 25, 2027) to regain compliance. The disclosure explicitly addresses failure to satisfy a continued listing rule and the risk of delisting if the stock price does not recover to at least $1.00 per share for 10 consecutive business days. This is a material event that directly threatens the company's continued listing status.
View raw filing on EDGAR →